Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential biologic agents for treating rheumatoid arthritis.

L W Moreland1

  • 1Arthritis Clinical Intervention Program, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. larry.moreland@ccc.uab.edu

Rheumatic Diseases Clinics of North America
|June 9, 2001
PubMed
Summary

Further studies on anti-tumor necrosis factor (TNF) therapies are needed to assess long-term safety and efficacy in modifying disease. Early intervention with targeted biologic agents may offer greater therapeutic benefits for rheumatoid arthritis (RA) patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis.

Genes and immunity·2015
Same author

Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial.

The pharmacogenomics journal·2013
Same author

Skeletal health among African Americans with recent-onset rheumatoid arthritis.

Arthritis and rheumatism·2009
Same author

Synovial Biopsy of the Knee Joint under Direct Visualization by Needle Arthroscopy.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Assessment of needle arthroscopy: comment on the pilot study by gramas et Al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

The use of methotrexate perioperatively in patients with rheumatoid arthritis undergoing major joint replacement surgery: will we ever have consensus about its use?

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is an immune-mediated disease characterized by joint destruction.
  • Anti-tumor necrosis factor (TNF) therapies have shown encouraging clinical results.
  • Understanding pathogenetic mechanisms in early and severe RA is crucial for developing better treatments.

Purpose of the Study:

  • To evaluate the long-term efficacy of TNF inhibitors in modifying RA's destructive component.
  • To assess the safety profile of long-term TNF inhibitor use.
  • To explore the potential of other biologic agents targeting specific cytokine pathways for improved RA treatment.

Main Methods:

  • Clinical trials evaluating anti-TNF therapies.
  • Long-term follow-up studies.

Related Experiment Videos

  • Ongoing evaluation of novel biologic agents targeting immune pathways in RA.

    • Main Results:

    • Anti-TNF therapy shows promise in managing RA.
    • Further research is warranted to confirm long-term benefits and safety.
    • Early intervention and targeted therapies are hypothesized to be more effective.

    Conclusions:

    • TNF inhibitors warrant further investigation for long-term RA management.
    • Targeting the cytokine cascade earlier in RA may enhance therapeutic outcomes.
    • Combination biologic therapies represent a promising avenue for future RA clinical trials.